12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xiaflex: Phase IIa data

Top-line data from an open-label, U.S. Phase IIa trial in 50 adults with stage 2 unilateral idiopathic frozen shoulder syndrome showed that 0.58 mg Xiaflex in 1 and 2 mL injection volumes given every 3 weeks for up to 3 injections plus shoulder exercises each met the primary endpoint of improving active forward flexion in the affected shoulder from baseline to day 92 vs. exercises alone (p<0.05 for both). Additionally, 0.58 mg (1 mL) Xiaflex plus exercise significantly improved shoulder abduction from baseline to day 92 vs. exercise alone (p<0.05), but the 0.58 mg (2 mL) dose was not significant on...

Read the full 481 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >